Indegene Limited’s Board has approved the unaudited standalone and consolidated financial results for Q2 2026. The board also approved share allotments under ESOP and RSU plans, an amendment to the Anti-Sexual Harassment Policy, and an investment of up to €8.5 million in Indegene Ireland Limited. The meeting concluded at 7:05 P.M. IST.
Q2 2026 Financial Performance
The Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The results include a limited review report from the auditors.
ESOP and RSU Allotments
The board approved the allotment of shares under the ESOP 2020 Plan and RSU 2020 Plan. The board also noted grants under the RSU 2020 Plan, ESOP 2020 Plan, and CSOP 2022 (CSOP Sub-Plan).
Policy Amendment and Investment
An amendment to the Anti-Sexual Harassment Policy was approved. Additionally, an investment in equity shares of Indegene Ireland Limited, a wholly-owned subsidiary, was approved for up to €8.5 million across one or more tranches.
Indegene Ireland Investment Details
Indegene will subscribe to equity shares of Indegene Ireland Limited at a face value of €1 per share, with the premium to be determined based on a valuation report from a registered valuer. The investment is aimed at supporting Indegene Ireland Limited’s capex requirements for business expansion, with completion targeted by December 31, 2026.
Financial Highlights (Consolidated)
Key figures from the consolidated financial results for the quarter ended September 30, 2025 include:
- Revenue from operations: ₹8,042 million
- Total income: ₹8,239 million
- Profit before tax: ₹1,331 million
- Profit for the period: ₹1,021 million
- Total comprehensive income: ₹1,505 million
Source: BSE
